11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Lopinavir/Ritonavir Accord

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Ritonavir

Ritonavir

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Teris. Ritonavir. Micromedex [www]. [cited 2022-04-22].

  2. The Antiretroviral Pregnancy Registry. Interim report 1 January 1989 through 31 July 2019. The Antiretroviral Pregnancy Registry [www]. [updated 2019-07-31, cited 2020-04-03].

  3. Garneau WM, Jones-Beatty K, Ufua MO, Mostafa HH, Klein SL, Burd I et al. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection. JAMA Netw Open. 2022;5(11):e2244141.

  4. Loza A, Farias R, Gavin N, Wagner R, Hammer E, Shields A. Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. 2022;140(3):447-449.

  5. EMA. Assessment report Paxlovid. EMA [www]. [updated 2021-12-16, cited 2022-04-14].

  6. Catlin NR, Bowman CJ, Campion SN, Cheung JR, Nowland WS, Sathish JG et al. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M. Reprod Toxicol. 2022;108(0):56-61.

  1. Teris. Ritonavir. Micromedex [www]. [cited 2022-04-22].
  2. The Antiretroviral Pregnancy Registry. Interim report 1 January 1989 through 31 July 2019. The Antiretroviral Pregnancy Registry [www]. [updated 2019-07-31, cited 2020-04-03].
  3. Garneau WM, Jones-Beatty K, Ufua MO, Mostafa HH, Klein SL, Burd I et al. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection. JAMA Netw Open. 2022;5(11):e2244141.
  4. Loza A, Farias R, Gavin N, Wagner R, Hammer E, Shields A. Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. 2022;140(3):447-449.
  5. EMA. Assessment report Paxlovid. EMA [www]. [updated 2021-12-16, cited 2022-04-14].
  6. Catlin NR, Bowman CJ, Campion SN, Cheung JR, Nowland WS, Sathish JG et al. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M. Reprod Toxicol. 2022;108(0):56-61.
2 2
2 2

Lopinavir

Lopinavir

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. The Antiretroviral Pregnancy Registry. Interim report 1 January 1989 through 31 July 2019. The Antiretroviral Pregnancy Registry [www]. [updated 2019-07-31, cited 2020-04-03].

  2. Tomi M, Nishimura T, Nakashima E. Mother-to-fetus transfer of antiviral drugs and the involvement of transporters at the placental barrier. J Pharm Sci. 2011;100:3708-18.

  3. Roberts SS, Martinez M, Covington DL, Rode RA, Pasley MV, Woodward WC. Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr. 2009;51:456-61.

  4. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. New Engl J Med 2002;346:1863-70.

  1. The Antiretroviral Pregnancy Registry. Interim report 1 January 1989 through 31 July 2019. The Antiretroviral Pregnancy Registry [www]. [updated 2019-07-31, cited 2020-04-03].
  2. Tomi M, Nishimura T, Nakashima E. Mother-to-fetus transfer of antiviral drugs and the involvement of transporters at the placental barrier. J Pharm Sci. 2011;100:3708-18.
  3. Roberts SS, Martinez M, Covington DL, Rode RA, Pasley MV, Woodward WC. Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr. 2009;51:456-61.
  4. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. New Engl J Med 2002;346:1863-70.